ASCO Breast Cancer
Conference Coverage
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancer
The endocrine-sensitive disease rate was similar whether patients received anastrozole alone, fulvestrant alone, or fulvestrant plus anastrozole...
Conference Coverage
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases
Conference Coverage
TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer
Conference Coverage
Capecitabine maintenance improved DFS, not OS, in TNBC patients
The 5-year disease-free survival rate was 83% in the capecitabine arm and 73% in the observation arm.
Conference Coverage
PPI added to chemo improves breast tumor response rate
Conference Coverage
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with...